文献速递心律失常心力衰竭与心肌病

双心室起搏与左束支区域起搏的心律失常风险比较:I-CLAS研究结果

Arrhythmic Risk in Biventricular Pacing Compared With Left Bundle Branch Area Pacing: Results From the I-CLAS Study.
PubMed 文献 · Circulation · 2023-11-11

I-CLAS研究比较了左束支区域起搏(LBBAP)与双心室起搏(BVP)在心脏再同步治疗患者中的持续性室速/室颤及新发房颤风险。倾向性评分匹配后,LBBAP组VT/VF发生率显著低于BVP组(4.2% vs 9.3%,HR 0.46),新发房颤>30秒发生率也显著降低(2.8% vs 6.6%,HR 0.34)。

要点

  • LBBAP较BVP显著降低持续性VT/VF风险(4.2% vs 9.3%,HR 0.46)。
  • LBBAP较BVP显著降低新发房颤>30秒风险(2.8% vs 6.6%,HR 0.34)。
  • LBBAP组VT风暴(24小时内>3次)发生率也显著低于BVP组(0.8% vs 2.5%)。

核心结论

  • LBBAP与较低的持续性VT/VF和新发房颤发生率相关,校正基线特征后差异仍显著。

研究设计与样本

  • I-CLAS研究为国际多中心研究,纳入2018年1月至2022年6月15个中心LVEF≤35%接受CRT的患者。
  • 共1778例患者(BVP 981例,LBBAP 797例),倾向性评分1:1匹配后1414例(每组707例)。

主要发现

  • 匹配队列中LBBAP组VT/VF发生率为4.2%,BVP组为9.3%(HR 0.46,95%CI 0.29-0.74,P<0.001)。
  • VT风暴(24小时内>3次)发生率LBBAP组0.8%,BVP组2.5%(P=0.013)。
  • 在无VT/VF病史且未用抗心律失常药的1194例患者中,LBBAP组VT/VF发生率3.2%,BVP组7.3%(HR 0.46,95%CI 0.26-0.81,P=0.007)。
  • 在无房颤病史的890例患者中,LBBAP组新发房颤>30秒发生率2.8%,BVP组6.6%(HR 0.34,95%CI 0.16-0.73,P=0.008)。
  • 房颤持续>24小时发生率LBBAP组0.7%,BVP组2.9%(P=0.015)。

关键数值与推荐

  • 在CRT起搏器亚组(BVP 111例,LBBAP 188例)中,VT/VF发生率BVP组7.2%,LBBAP组0%(P<0.001)。

临床怎么用

  • 对于需CRT且LVEF≤35%的患者,LBBAP可能较BVP降低室性心律失常和房颤风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Left bundle branch area pacing (LBBAP) may be associated with greater improvement in left ventricular ejection fraction and reduction in death or heart failure hospitalization compared with biventricular pacing (BVP) in patients requiring cardiac resynchronization therapy. We sought to compare the occurrence of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) and new-onset atrial fibrillation (AF) in patients undergoing BVP and LBBAP. METHODS: The I-CLAS study (International Collaborative LBBAP Study) included patients with left ventricular ejection fraction ≤35% who underwent BVP or LBBAP for cardiac resynchronization therapy between January 2018 and June 2022 at 15 centers. We performed propensity score-matched analysis of LBBAP and BVP in a 1:1 ratio. We assessed the incidence of VT/VF and new-onset AF among patients with no history of AF. Time to sustained VT/VF and time to new-onset AF was analyzed using the Cox proportional hazards survival model. RESULTS: Among 1778 patients undergoing cardiac resynchronization therapy (BVP, 981; LBBAP, 797), there were 1414 propensity score-matched patients (propensity score-matched BVP, 707; propensity score-matched LBBAP, 707). The occurrence of VT/VF was significantly lower with LBBAP compared with BVP (4.2% versus 9.3%; hazard ratio, 0.46 [95% CI, 0.29-0.74]; P<0.001). The incidence of VT storm (>3 episodes in 24 hours) was also significantly lower with LBBAP compared with BVP (0.8% versus 2.5%; P=0.013). Among 299 patients with cardiac resynchronization therapy pacemakers (BVP, 111; LBBAP, 188), VT/VF occurred in 8 patients in the BVP group versus none in the LBBAP group (7.2% versus 0%; P<0.001). In 1194 patients with no history of VT/VF or antiarrhythmic therapy (BVP, 591; LBBAP, 603), the occurrence of VT/VF was significantly lower with LBBAP than with BVP (3.2% versus 7.3%; hazard ratio, 0.46 [95% CI, 0.26-0.81]; P=0.007). Among patients with no history of AF (n=890), the occurrence of new-onset AF >30 s was significantly lower with LBBAP than with BVP (2.8% versus 6.6%; hazard ratio, 0.34 [95% CI, 0.16-0.73]; P=0.008). The incidence of AF lasting >24 hours was also significantly lower with LBBAP than with BVP (0.7% versus 2.9%; P=0.015). CONCLUSIONS: LBBAP was associated with a lower incidence of sustained VT/VF and new-onset AF compared with BVP. This difference remained significant after adjustment for differences in baseline characteristics between patients with BVP and LBBAP. Physiological resynchronization by LBBAP may be associated with lower risk of arrhythmias compared with BVP.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Herweg B, Sharma PS, Cano Ó, et al. Arrhythmic Risk in Biventricular Pacing Compared With Left Bundle Branch Area Pacing: Results From the I-CLAS Study. Circulation. 2023. PMID: 37950738. doi:10.1161/CIRCULATIONAHA.123.067465

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。